The global burden of disease study 2013: What does it mean for the NTDs? by Herricks, J.R. (Jennifer R.) et al.
VIEWPOINTS
The global burden of disease study 2013:
What does it mean for the NTDs?
Jennifer R. Herricks1,2*, Peter J. Hotez1,2,3,4,5, Valentine Wanga6, Luc E. Coffeng6,7,
Juanita A. Haagsma6,7, Marı´a-Gloria Basa´ñez8, Geoffrey Buckle9, Christine M. Budke10,
He´lène Carabin11, Eric M. Fèvre12,13, Thomas Fu¨rst14,15,16, Yara A. Halasa17, Charles
H. King18, Michele E. Murdoch19, Kapa D. Ramaiah20, Donald S. Shepard17, Wilma
A. Stolk6, Eduardo A. Undurraga17, Jeffrey D. Stanaway6, Mohsen Naghavi6*, Christopher
J. L. Murray6
1 Department of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine,
Baylor College of Medicine, Houston, Texas, United States of America, 2 James A. Baker III Institute for
Public Policy, Rice University, Houston, Texas, United States of America, 3 Texas Children’s Hospital Center
for Vaccine Development, Houston, Texas, United States of America, 4 Scowcroft Institute of International
Affairs, Bush School of Government and Public Service, Texas A&M University, College Station, Texas,
United States of America, 5 Department of Biology, Baylor University, Waco, Texas, United States of
America, 6 Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United
States of America, 7 Department of Public Health, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, The Netherlands, 8 London Centre for Neglected Tropical Disease Research, Department of
Infectious Disease Epidemiology, Imperial College London, London, United Kingdom, 9 University of
California, San Francisco, San Francisco, California, United States of America, 10 Department of Veterinary
Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University,
College Station, Texas, United States of America, 11 Department of Biostatistics and Epidemiology, College
of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
of America, 12 International Livestock Research Institute, Nairobi, Kenya, 13 Institute of Infection and Global
Health, University of Liverpool, Liverpool, United Kingdom, 14 School of Public Health, Imperial College
London, London, United Kingdom, 15 Department of Epidemiology and Public Health, Swiss Tropical and
Public Health Institute, Basel, Switzerland, 16 University of Basel, Basel, Switzerland, 17 Schneider
Institutes for Health Policy, Brandeis University, Waltham, Massachusetts, United States of America,
18 Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland,
Ohio, United States of America, 19 Department of Dermatology, Watford General Hospital, Watford, Herts,
United Kingdom, 20 Consultant on Lymphatic Filariasis, Tagore Nagar, Pondicherry, India
* jennifer.herricks@yahoo.com (JRH); nagham@uw.edu (MN)
The new Global Burden of Disease Study 2013 has identified some key trends in the major
neglected tropical diseases, many with public health and policy implications.
The Global Burden of Disease Study (GBD) is a landmark initiative that systematically quanti-
fies the prevalence, morbidity, and mortality for hundreds of diseases, injuries, and risk factors
of global health importance. For the neglected tropical diseases (NTDs), the GBD 2010 con-
firmed a high disease burden for the 17 major NTDs prioritized by the World Health Organi-
zation (WHO) as well as for selected conditions also recognized as NTDs by PLOS Neglected
Tropical Diseases, including amoebiasis, cholera, cryptosporidiosis, typhoid and paratyphoid
fevers, trichomoniasis, venomous animal contact, and scabies (referred to here as “additional
NTDs”) [1]. The GBD 2013 is intended to be the first in a series of annual updates for the GBD
studies, with its initial results published in 2015 in The Lancet [2–4]. Here, we review informa-
tion on the NTDs published in the GBD 2013 capstone papers [2–4] and present new NTD
data and updated burden estimates from the GBD 2013 study and new country-specific esti-
mates. We show key outputs of GBD 2013 including country-specific estimates of prevalence
or incidence and health-gap metrics for the aforementioned NTDs.
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Global prevalence and trends for NTDs in 2013
GBD 2013 estimates suggest that NTDs are among the world’s most common conditions, with
more than 2 billion prevalent NTD infections globally in 2013 (Table 1). The 3 major intestinal
helminth infections—ascariasis, trichuriasis, and hookworm infection—account for 1.75 bil-
lion of those cases, comprising more than three-quarters of the total prevalent NTD infections.
Also highly prevalent are schistosomiasis, foodborne trematodiases, lymphatic filariasis (LF),
and onchocerciasis as well as dengue fever [3]. In total, there are 2.3 billion cases of the WHO-
Table 1. Prevalent cases of NTDs in 2013 and percent change from 1990 to 2013 according to the
Global Burden of Disease Study (GBD) 2013 [3].
Disease Prevalent cases (in millions) in
2013
Percent change since
1990
Ascariasis 804.4 −25.5%
Trichuriasis 477.4 −11.6%
Hookworm 471.8 −5.1%
Schistosomiasis 290.6 30.9%
Foodborne trematodiases 80.2 51.1%
Dengue*† 58.4 610.9%
Lymphatic filariasis 43.9 −32.1%
Onchocerciasis 17.0 −31.2%
Chagas disease 9.4 22.4%
Cutaneous/mucocutaneous leishamaniasis 3.9 174.2%
Trachoma† 2.4 −39.2%
Cysticercosis† 1.0 −26.3%
Cystic echinococcosis† 0.8 −15.4%
Leprosy 0.7 61.3%
Visceral leishmaniasis 0.1 35.1%
Rabies*† 0.02 −40.4%
African trypanosomiasis 0.02 −71.1%
Other NTDs 59.7 −5.0%
Total cases 2,322 NA
Additional NTDs Prevalent cases (in millions) in
2013
Percent change since
1990
Trichomoniasis 67.1 45.6%
Scabies 66.1 24.8%
Typhoid fever* 11.0 −19.9%
Paratyphoid fever* 6.4 −27.9%
Venomous animal contact* 5.5 −2.7%
Cholera* 2.3 6.1%
Cryptosporidiosis* 1.4 −19.4%
Amoebiasis* 0.4 17.0%
Total cases of additional neglected
diseases
160.2 NA
* Incident cases in 2013 rather than prevalent cases.
† Symptomatic cases only.
NOTE: For information on percent change calculations, see GBD 2013 capstone paper on incidence,
prevalence, and years lived with disability (YLDs) [3]. All data presented in this table (except for rabies,
cholera, cryptosporidiosis, and amoebiasis) are also available from the Institute for Health Metrics and
Evaluation (IHME) website and were previously published in [3]. Abbreviations: NA, non-applicable
https://doi.org/10.1371/journal.pntd.0005424.t001
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prioritized NTDs plus “other NTDs” globally in 2013 and at least 160 million cases of addi-
tional neglected diseases.
GBD 2013 reveals some major and notable changes in prevalence or incidence of these dis-
eases since 1990. The most notable is a 610% increase in dengue fever incidence, consistent
with the widespread emergence of this disease in Asia, Africa, and the Americas beyond what
would be expected due to changes in population demographics. Overall, the major Southeast
Asian countries exhibit the highest incidence, as do selected countries in the Caribbean, Cen-
tral America, and tropical areas of South America (Fig 1). South Asia and West African coun-
tries bordering the Gulf of Guinea also exhibit high incidence. In addition, there has been a
nearly 175% increase in the estimated number of prevalent cases of cutaneous and mucocuta-
neous leishmaniasis, which is associated with the major increases from 1990–2013 in the con-
flict areas of the Middle East and Central Asia (Afghanistan: 138%, Iraq: 1,293%, and Syria:
1,660%) and in East Africa (Sudan: 2,009%). The marked increases in these countries may be
linked to conflict-associated collapsed health systems and/or increases in reporting rates over
time [5–8]. The increase in prevalence of cutaneous and mucocutaneous leishmaniasis by
country is shown in Fig 2. Marked increases of over 50% in the estimated number of prevalent
cases were also noted for leprosy and foodborne trematodiases.
GBD 2013 found that there have been substantial reductions (approximately 30%–40%) in
prevalent cases of trachoma-attributable vision impairment, LF, and onchocerciasis. There
were also considerable reductions in ascariasis, which a previous analysis has associated with
trends in China [9]. These changes relate to increases in mass drug administration (MDA)
programs over the last decade [10] both as school-based and community-based programs, the
latter also due to the scaling up of LF and onchocerciasis control and elimination efforts (asca-
ris is susceptible both to benzimidazoles and to ivermectin). Considering the progress of these
control and elimination programs, we expect to see a further reduction in disease burden and
possibly elimination of disease transmission in the coming years in many countries [11–14].
However, to date, there has been no substantial impact on the prevalence of schistosomiasis
and only modest impact for 2 of the soil-transmitted helminth infections (STHs)—hookworm
and trichuriasis.
Fig 1. Global dengue incidence per 100,000 person-years in 2013. Adapted from Stanaway et al. [40]. NOTE: No estimates are available for Western
Sahara as it was not a modeled location in the Global Burden of Disease Study (GBD) 2013.
https://doi.org/10.1371/journal.pntd.0005424.g001
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Finally, other major trends noted in GBD 2013 include a 71% reduction in the number of
cases of human African trypanosomiasis (HAT) infection. HAT is another NTD for which
elimination may be plausible—especially the Gambian form—through case detection and
treatment [15]. There have also been reductions in the number of cases of disease from rabies,
cysticercosis, and cystic echinococcosis since 1990. However, cysticercosis and cystic echino-
coccosis still cause substantial morbidity (years lived with disability [YLDs]) and rabies contin-
ues to cause substantial mortality (see section Death and DALY Trends for NTDs in 2013
below for more information in YLDs, years of life lost [YLLs], disability-adjusted life years
[DALYS], and deaths).
Regional prevalence and incidence distribution in 2013
GBD 2013 further identified the regions most affected by NTDs. Figs 3 and 4 highlight the dis-
ease-endemic countries burdened with either the highest prevalence (prevalent cases per
100,000 population), incidence (incident cases per 100,000 person-years) (Fig 3), or absolute
number of cases (Fig 4) of NTDs. As one would expect, the burden of disease in DALYs was
closely correlated to the number of cases.
As shown in Fig 4, India has the greatest number of cases of at least 10 different NTDs, fol-
lowed by China (3), Democratic Republic of Congo (DRC) (2), and 1 each for Afghanistan,
Brazil, and Nigeria. These numbers, while reflective of absolute burden, conflate disease preva-
lence and population size. By contrast, Fig 3 highlights areas where the prevalence of infection
are highest, including less populous countries in sub-Saharan Africa, the Middle East and
North Africa (MENA), Southeast and Central Asia, and the surprisingly high prevalence of
helminth infections in Oceania. We next provide specific observations for each of the major
NTD categories.
Prevalence of helminth infections
The prevalence of the STH infections—trichuriasis, hookworm infection, and ascariasis—is
especially high in Oceania, Southeast Asia, and South Asia. Large middle-income countries
Fig 2. Global cutaneous/mucocutaneous leishmaniasis prevalence per 100,000 population in 2013. NOTE: No estimates are available for Western
Sahara as it was not a modeled location in the Global Burden of Disease Study (GBD) 2013.
https://doi.org/10.1371/journal.pntd.0005424.g002
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Fig 3. Countries with highest NTD prevalence in 2013. Countries with the highest prevalence (per 100,000 population) for the diseases indicated and the
estimated prevalence in each country. Countries are color coded by Global Burden of Disease Study (GBD) regions. Abbreviations: CAR, Central African
Republic; DRC, Democratic Republic of the Congo; STP, São Tome´ and Principe. *Also includes mucocutaneous leishmaniasis, **Incidence rather than
prevalence.
https://doi.org/10.1371/journal.pntd.0005424.g003
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Fig 4. Countries with highest absolute number of NTD cases in 2013. Countries with the highest number of absolute cases for the diseases indicated
and the estimated numbers in each country. These data are also available from the Institute for Health Metrics and Evaluation (IHME) website. Countries are
color coded by Global Burden of Disease Study (GBD) regions. Abbreviations: CAR, Central African Republic; DRC, Democratic Republic of the Congo;
STP, São Tome´ and Principe. *Also includes mucocutaneous leishmaniasis, **Incident cases rather than prevalent cases, NOTE: As in Table 1, only
symptomatic cases are estimated for dengue, trachoma, cystic echinococcosis, cysticercosis, and rabies.
https://doi.org/10.1371/journal.pntd.0005424.g004
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such as India and China as well as Bangladesh, Indonesia, and the Philippines stand out for
having the largest numbers of cases of these infections.
While India has the largest number of LF cases (with infections estimated at 7.1 million),
LF prevalence is highest in Zambia and Eritrea. China and the Southeast Asian countries of
Thailand and Laos exhibit the largest number of cases of foodborne trematodiases (FBT), with
67.3 million cases in China alone. Thailand and Laos also have the greatest prevalence of FBT.
The largest numbers of cases of schistosomiasis infection are in Nigeria with 73 million cases,
followed by Ethiopia, the DRC, and Kenya, while countries with the highest prevalence of
schistosomiasis infection are Angola and Gabon of central sub-Saharan Africa followed by
several countries in eastern sub-Saharan Africa. The DRC leads in the number of cases of
onchocerciasis infection, estimated at 8.3 million, and also has the third highest prevalence of
infection behind Liberia and South Sudan. India and China lead the world in cysticercosis and
cystic echinococcosis disease cases with over 100,000 each, while Burkina Faso has the highest
prevalence of disease from cysticercosis and Mongolia has the highest prevalence of disease
from cystic echinococcosis.
Prevalence of protozoan infections
Among the 3 kinetoplastid infections, India has the largest number of visceral leishmaniasis
(VL) cases at 62,000, although South Sudan and Sudan lead in prevalence. Brazil and Argen-
tina have the largest number of Chagas disease infections with nearly 2 million cases each,
while Bolivia has by far the highest prevalence—over 8,000 cases per 100,000 people. DRC has
the largest number of absolute cases of prevalent and incident infections from HAT, estimated
at 14,000 and 10,700, respectively. The Central African Republic had the highest prevalence
and incidence of HAT infections in 2013.
Incidence and prevalence of viral and bacterial infections
India leads the world in number of dengue fever cases with 18.6 million followed by Indonesia
with 11.1 million, with Oceania and Southeast Asian countries leading in terms of incidence.
India has the largest number of trachoma cases at about 758,000, followed by Ethiopia, with
the Sahelian nations of Ethiopia, South Sudan, and Mali leading in terms of prevalence. It is
important to note here that GBD 2013 estimates for this disease only represent the prevalence
of blindness and vision impairment due to trachoma. The largest numbers of rabies cases
occur in India (with over 12,000), China, Pakistan, and Nigeria, while Myanmar and the Sahel-
ian nations of Chad, Niger, and Somalia lead in terms of incidence. India, Brazil, and Indone-
sia have the largest number of prevalent cases of leprosy in the world at 333,000, 63,000, and
43,000, respectively, as well as incident cases. South Sudan and Madagascar lead in terms of
disease prevalence, while the Oceanic countries of the Marshall Islands, Federated States of
Micronesia, and Kiribati lead in terms of disease incidence.
Prevalence of other NTDs
Included in the group of “other NTDs” are a variety of diseases ranging from arthropod-borne
viral infections to bacterial relapsing fevers to unspecified protozoan diseases and a variety of
helminthic diseases for which limited disease burden data are available. Nevertheless, these dis-
eases have an enormous impact. India has the highest number of cases of these diseases at 16.1
million, followed by China and Indonesia. Afghanistan and Yemen lead in terms of disease
prevalence rates, followed by countries in western sub-Saharan Africa.
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NTD-associated deaths in 2013
Table 2 shows the estimated numbers of deaths and the age-standardized death rates in 2013
due to the 17 NTDs prioritized by WHO and other NTDs.
In all, it was estimated that 141,800 deaths could be attributable to the 17 NTDs prioritized
by the WHO plus “other NTDs” in 2013. However, if the additional NTDs such as typhoid
fever, cholera, paratyphoid fever, cryptosporidiosis, and amoebiasis are also included among
the diseases in Table 2, together they are estimated to have caused over 500,000 deaths in 2013,
roughly equivalent to the number of deaths from all motor vehicle road injuries or breast can-
cer and more than half of the malaria deaths [4]. The leading NTD killers in 2013 were VL,
rabies, and Chagas disease. Among those neglected diseases not prioritized by the WHO in
Table 2. Number of deaths and age-standardized death rates for NTDs in 2013 with percent change from 1990 to 2013 [4].
NTDs Deaths in
2013
Percent change since
1990
Age-standardized deaths per 100,000
in 2013
Percent change since
1990
Visceral leishmaniasis 62,500 19.8% 0.86 −0.3%
Rabies 23,500 −38.3% 0.34 −54.0%
Chagas disease 10,600 −19.3% 0.17 −51.7%
Dengue 9,100 −1.3% 0.13 −13.6%
African trypanosomiasis 6,900 −69.7% 0.08 −78.9%
Schistosomiasis 5,500 −68.2% 0.08 −80.7%
Ascariasis 4,500 −50.7% 0.06 −54.7%
Cystic echinococcosis 2,200 −45.0% 0.03 −60.8%
Cysticercosis 700 −28.6% 0.01 −53.0%
Hookworm* 0 NA 0 NA
Trichuriasis* 0 NA 0 NA
Foodborne trematodiases* 0 NA 0 NA
Lymphatic filariasis* 0 NA 0 NA
Onchocerciasis* 0 NA 0 NA
Cutaneous/mucocutaneous leishmaniasis* 0 NA 0 NA
Trachoma* 0 NA 0 NA
Leprosy* 0 NA 0 NA
Other NTDs 16,300 −54.4% 0.24 −62.3%
Total deaths from NTDs 141,800 NA NA NA
Additional neglected diseases Deaths in
2013
Percent change since
1990
Age-standardized deaths per 100,000
in 2013
Percent change since
1990
Typhoid fever 160,700 −10.8% 2.21 −25.9%
Venomous animal contact 57,200 −25.0% 0.82 −51.8%
Cholera 69,900 −44.3% 0.97 −51.9%
Paratyphoid fever 54,300 −14.9% 0.75 −28.0%
Cryptosporidiosis 41,900 −57.8% 0.58 −59.8%
Amoebiasis 11,300 −39.1% 0.18 −58.3%
Scabies* 0 NA 0 NA
Trichomoniasis* 0 NA 0 NA
Total deaths from additionalneglected
diseases
395,300 NA NA NA
*Negligible evidence of deaths according to the Global Burden of Disease Study (GBD) 2013.
NOTE: For information on percent change calculations, see GBD 2013 capstone paper on mortality [4]. The estimates presented in this table are also
available from the Institute for Health Metrics and Evaluation (IHME) website and previously published in [4]. Abbreviations: NA, non-applicable
https://doi.org/10.1371/journal.pntd.0005424.t002
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2013, typhoid fever, cholera, and venomous animal contact were responsible for the largest
number of deaths. A particularly disturbing trend was noted for VL, for which the number of
cases, deaths, and YLDs have increased since 1990 (Tables 1–3). Rates, however, have been
effectively static, suggesting that the increase in absolute numbers may also be due to demo-
graphic changes such as population growth and changes in population age structure. However,
this finding also shows how little progress has been made in fighting this infection.
When considered in terms of age and sex, the highest mortality caused by NTDs is also due
to VL, primarily in the young, and Chagas disease, primarily in the elderly (Fig 5). “Other
Table 3. Leading causes of disability-adjusted life years (DALYs) resulting from the NTDs according to the Global Burden of Diseases Study
(GBD) 2013 with attributing years lived with disability (YLDs) and years of life lost (YLLs) [2–4].
NTD DALYs (in millions) in
2013
Percent change for DALYs
2005–2013
YLDs (in millions) in
2013
YLLs (in millions) in
2013
Visceral leishmaniasis 4.24 8.7% 0.008 4.23
Foodborne trematodiases 3.63 14.6% 3.63 0
Schistosomiasis 3.06 −13.9% 2.86 0.2
Hookworm 2.18 −0.5% 2.18 0
Lymphatic filariasis 2.02 −14.3% 2.02 0
Ascariasis 1.27 −29.0% 0.93 0.34
Rabies 1.24 −14.6% 0.0001 1.24
Onchocerciasis 1.18 −19.4% 1.18 0*
Dengue 1.14 17.0% 0.56 0.58
Trichuriasis 0.58 −12.3% 0.58 0
African trypanosomiasis 0.39 −54.3% 0.005 0.38
Chagas disease 0.34 4.6% 0.10 0.24
Cysticercosis 0.34 −16.4% 0.31 0.03
Cystic echinococcosis 0.18 −14.1% 0.08 0.1
Trachoma 0.17 −18.1% 0.17 0
Cutaneous and mucocutaneous
leishmaniasis
0.04 35.9% 0.04 0
Leprosy 0.04 8.6% 0.04 0
Other NTDs 3.13 −11.8% 2.26 0.87
Total NTDs 25.17 NA 16.95 8.21
Additional neglected diseases DALYs (in millions) in
2013
Percent change for DALYs
2005–2013
YLDs (in millions) in
2013
YLLs (in millions) in
2013
Typhoid fever 11.13 −13.7% 0.16 10.97
Cholera 5.17 −20.1 0.04 5.13
Paratyphoid fever 3.82 −8.0% 0.04 3.78
Cryptosporidiosis 3.46 −29.6 0.19 3.27
Venomous animal contact 3.00 −3.4% 0.15 2.85
Scabies 1.71 4.8% 1.71 0
Amoebiasis 0.38 −23.8% 0.04 0.34
Trichomoniasis 0.11 8.2% 0.11 0
Total deaths from additional neglected
diseases
28.78 NA 2.44 26.34
NOTE: For information on percent change calculations, see the Global Burden of Disease Study (GBD) 2013 capstone paper on DALYs [2]. The estimates
presented in this table are also available on the Institute for Health Metrics and Evaluation (IHME) website and were previously published in [2–4].
Information on DALYs and YLDs for Cholera, Cryptosporidiosis, and Amoebiasis is not available from IHME website or capstone papers. Abbreviations:
NA, non-applicable
https://doi.org/10.1371/journal.pntd.0005424.t003
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NTDs” also caused higher mortality with increased age. Rabies caused substantial mortality
across all ages and ascariasis was primarily a cause of mortality for children under 5 years of
age. In general, for the other NTDs listed, mortality is highest in the youngest and oldest
populations.
DALY trends for NTDs in 2013
As shown in Table 3, the GBD 2013 estimates for NTDs result in approximately 25 million
DALYs, which is greater than the DALYs attributable to liver cancer, for instance [2]. The
leading NTDs in terms of DALYs include VL, foodborne trematodiases, schistosomiasis,
hookworm disease, and LF [2]. Among the additional neglected diseases, typhoid fever and
cholera each cause more DALYs than VL. In addition, Table 3 shows the global burden of
these diseases in terms of YLDs and YLLs. Onchocerciasis, the sixth highest cause of YLDs,
was ranked highly in Liberia, Cameroon, and South Sudan in the top 10 leading causes of
Fig 5. Deaths per 100,000 population by age and sex in 2013. The data used to generate this figure are also available on the Institute for Health
Metrics and Evaluation (IHME) website.
https://doi.org/10.1371/journal.pntd.0005424.g005
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YLDs by country, predominantly due to onchocercal skin disease [3]. For most NTDs, YLDs
account for a greater proportion of DALYs than do YLLs, and the most prevalent diseases (see
Table 1) are also the ones that cause the most disability. In total, NTDs were responsible for 17
million YLDs and 8 million YLLs in 2013.
Evaluating the etiologic composition of DALYs by age, we see that VL dominates among
the very young (<5 years), but ascariasis, dengue, rabies, and “other NTDs” are also important
NTDs among pediatric age groups (Fig 6). For older school-aged children and adolescents,
STH infections and schistosomiasis are the leading causes of DALYs. Among adults, food-
borne trematodiases, LF (especially in males), and hookworm infection represent some of the
highest disease burdens due to NTDs. Among adolescent and adult women, schistosomiasis
and hookworm infection are also leading causes of DALYs. For hookworm infection, it is likely
that the adult-onset DALYs are linked to its high prevalence among adults and the associated
high risk of anemia in pregnant and lactating women [16]. Further, DALYs for schistosomiasis
Fig 6. Disability-adjusted life years (DALYs) per 100,000 population by age and gender in 2013. The estimates used to generate this figure are
also available on the Institute for Health Metrics and Evaluation (IHME) website.
https://doi.org/10.1371/journal.pntd.0005424.g006
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may have been even higher if the GBD 2013 considered female genital schistosomiasis, perhaps
Africa’s most common chronic gynecological disease, in these estimates [16].
Finally, Fig 7 shows the geographic distribution of DALYs per 100,000 population in 1990
and 2013 from all NTDs listed in Figs 3 and 4. Decreases were noted for each region from 1990
to 2013. The darker shading represents the portion of YLLs for these diseases, while the lighter
shading represents the YLDs (by percentage of the DALYs). In each region, it is clear that
the overwhelming majority of NTD-attributable DALYs arise from YLDs. Interestingly, the
DALYs in South Asia are composed of almost equal numbers of YLDs and YLLs, likely due to
the high prevalence of VL and other fatal NTDs in that region. In most super regions,
Fig 7. Proportional representation of disability-adjusted life years (DALYs) (per 100,000 population) from all NTDs combined in 1990 and 2013
by Global Burden of Disease Study (GBD) super region. Each bar represents the total disability-adjusted life years (DALYs) per 100,000 population
for WHO-prioritized NTDs combined by GBD super region, broken down by percentage of years of life lost (YLLs) (darker shading) and years lived with
disability (YLDs) (lighter shading). GBD-estimated numbers for DALY, YLL, and YLD rates for each super region in 1990 and 2013 are shown in the key.
https://doi.org/10.1371/journal.pntd.0005424.g007
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especially those with the most DALYs from NTDs, DALYs were nearly halved from 1990 to
2013. While this clearly represents progress, Fig 7 also makes it clear that there is a lot of work
to be done to reduce the substantial burden of these diseases, especially in sub-Saharan Africa
and throughout Asia.
Considerations and limitations of the GBD 2013 results for NTDs
Our overall objective in this article is not to provide an in-depth critique of GBD 2013 method-
ology or data but rather to highlight findings that we consider of importance for the NTDs
community. The GBD category of “other NTDs” includes a range of other neglected tropical
diseases (relapsing fevers, typhus fever, spotted fever, Q fever, other rickettsioses, other mos-
quito-borne viral fevers, unspecified arthropod-borne viral fever, arenaviral haemorrhagic
fever, toxoplasmosis, unspecified protozoal disease, taeniasis, diphyllobothriasis and spargano-
sis, other cestode infections, dracunculiasis, trichinellosis, strongyloidiasis, enterobiasis, and
other helminthiases) but these are not modeled separately. No information from the GBD
2013 is currently available for Buruli ulcer, chikungunya virus (included under “other NTDs”),
and yaws. Unless stated otherwise, estimates presented are for both symptomatic and asymp-
tomatic cases.
Countries with the lowest NTD burden often lie within the high-income super region.
However, we have noted previously that surprisingly high rates of NTDs also occur among the
poorest residents of the world’s largest economies: the Group of 20 nations (G20) plus Nigeria
and other wealthy countries in the MENA, Asia, and the Americas (the concept of “blue mar-
ble health”) [17]. The GBD 2013 confirms that high NTD burden occurs within the G20
nations and Nigeria [18]. However, gaps in the estimates remain. For example, GBD 2013 esti-
mates for Chagas disease were restricted to endemic countries, and no estimates were made of
imported cases in countries with large Latin American immigrant populations, such as the
United States and Spain. However, the U.S. Centers for Disease Control and Prevention
(CDC) estimates that there are at least 200,000 cases of Chagas disease in the US, which would
place the US as the country with among the highest number of cases in the world [19]. In addi-
tion, there is evidence of triatomine insects infected with Trypanosoma cruzi and positive for
human blood, as well as autochthonous transmission of Chagas disease in the US, especially in
Texas [20]. Unfortunately, reporting of Chagas disease in the US is low, likely due to a lack of
healthcare provider knowledge of the disease [21]. The exclusion of imported cases from
nonendemic countries as well as underreporting of autochthonous transmission suggests that
GBD 2013 is underestimating Chagas prevalence globally.
Also of interest is the impact of MDA for intestinal helminth infections, schistosomiasis,
LF, onchocerciasis, and trachoma, which has been integrated and expanded on a global scale
beginning in 2006 through financial support of the governments of the US (United States
Agency for International Development’s NTD Program) and the United Kingdom [22]. Con-
trol through MDA started at different time points for different diseases and countries, so prog-
ress has been heterogeneous [23]. For example, large-scale vector control for onchocerciasis
(Onchocerciasis Control Programme in West Africa, OCP) started in West Africa in the mid-
1970s. From 1995 onwards, the African Programme for Onchocerciasis Control (APOC) coor-
dinated the gradual scale-up of MDA with ivermectin in the remaining endemic African coun-
tries and the OCP used ivermectin to control any recrudescence. By now, a majority of areas
in need of treatment for onchocerciasis are receiving MDA [24–26]. The Global Program to
Eliminate Lymphatic Filariasis (GPELF) has been in place since 2000, while large-scale treat-
ment for STH infections and schistosomiasis started later [27]. Following its successful large-
scale use in Morocco, MDA of azithromycin has been included as part of WHO’s surgery,
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antibiotics, facial cleanliness, and environmental improvement (SAFE) strategy for eliminating
trachoma [28–32]. The trends we see for the major helminth infections may be potentially
explained by the relatively recent start of widespread schistosomiasis control programs and
low single-dose drug efficacies for hookworm and trichuriasis [33, 34], given that we are
already seeing substantial reductions in ascariasis, as highlighted above.
We also point out that prevalence estimates for HAT and leprosy for the GBD 2013 are
derived in part from reported incidence figures and literature-based assumptions about the
natural history of these diseases.
It is important to note that the GBD 2013 cysticercosis estimates only include cases of neu-
rocysticercosis (NCC)-associated epilepsy, although this brain infection may cause several
other neurological disorders [35]. The GBD estimates are based on the estimated prevalence of
secondary epilepsy and the prevalence of NCC among people living with secondary epilepsy.
Because not all infections of cysticercosis result in NCC, it is likely that there are more cysticer-
cosis cases than those estimated by GBD 2013. Likewise, not all cases of NCC are associated
with epilepsy but rather with severe chronic headaches, stroke, focal deficit, and dementia, to
name a few conditions. Because such cases were not included in the current estimates, this
may have led to an underestimation of the burden of cysticercosis by the GBD 2013. Moreover,
this means that part of the disability incurred by other neurological and mental health disor-
ders caused by NCC increases the DALYs of these diseases, making other disorders look less
important. Cysticercosis estimates are based on sparse literature data on NCC prevalence
among people with epilepsy (from 12 countries: Bolivia, Brazil, Burkina Faso, Colombia, Ecua-
dor, Guatemala, Honduras, India, Mexico, Peru, South Africa, and Tanzania) combined with
country-level covariate data on access to sanitation and proportion of the population that is
Muslim. It has been pointed out appropriately by 1 of the reviewers for this manuscript that
intermediate-host pig populations should be considered rather than a proportion of Muslim
populations in order to adequately capture nations such as Chad, Ethiopia, and Sudan that
have significant non-Muslim populations yet also have very few pigs. Unfortunately, none of
these indicators measure precisely the risk factor of most interest for NCC, which is the expo-
sure of humans to livable Taenia solium eggs in the environment. Such exposure, in turn,
depends on the level of sanitation and the prevalence of human (T. solium) taeniasis in the
population. The prevalence of taeniasis depends in turn on the consumption of undercooked
pork meat. Therefore, although the presence of pigs may act as an indirect yet important indi-
cator of NCC, it is not the only one. Other factors also play a role (people might eat well-
cooked pork, which is common when the meat is consumed at home, or pigs may not ever be
exposed to human feces in areas where their access to human feces is restricted). Better esti-
mates of the burden of NCC will be feasible as more data on the actual prevalence of NCC-
associated neurological disorders becomes available with the development of better diagnosis
for infections of the brain [36]. Another challenge is that the very clustered nature of cysticer-
cosis, NCC, and taeniasis makes it difficult to generalize data from small-scale studies to larger
areas, making it difficult to evaluate the true burden of cysticercosis.
Similar to cysticercosis, the GBD 2013 cystic echinococcosis estimates relied heavily on
modeling approaches to fill in data gaps. While this method does allow for a regional picture
of where the condition is more prevalent, many individual country-level estimates will require
additional verification and refinement. One example of where country-level estimates will
need to be improved is in Asia. While portions of China and Central Asia are known to be
highly endemic for cystic echinococcosis, most countries in Southeast Asia (e.g., Indonesia,
Thailand, and Vietnam) are believed to be nonendemic for this disease. This observation is evi-
denced by both the lack of reports of autochthonous human cases from these countries and no
reported animal infections. However, based on GBD country-level covariate information used
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to fill in data gaps, the numbers of estimated cases in these countries appear to be high,
whereas current data indicate that there are few or no cases. The surprisingly high cystic echi-
nococcosis case numbers predicted for Indonesia are an example of this phenomenon.
In 2010, the WHO Foodborne Disease Burden Epidemiology Reference Group (FERG)
released their own calculations for the burden of foodborne diseases such as cysticercosis and
cystic echinococcosis [37]. The difference in DALY estimates for some diseases between the
FERG estimates and GBD 2010 were striking [2, 38]. For cysticercosis, the GBD 2010 esti-
mated 514,000 DALYs, whereas the FERG study estimated over 2.7 million DALYs. The GBD
2013 estimates 340,000 DALYs for cysticercosis—still far off from the FERG estimates. The
FERG study used some of the same input data as GBD study, similar analytical methods, and
many of the same weightings [39]. However, some different and important choices were
made. In the case of cysticercosis, the FERG study allocated a much larger proportion of the
epilepsy burden to cysticercosis, based on data from a systematic review [40]. Such differences
may be considered important with respect to assessing changing burden over time and high-
light the need to align methodologies in an open and transparent fashion.
For several NTDs, the number of deaths reported by the GBD 2013 is also likely to repre-
sent an underestimate. For example, urogenital schistosomiasis is a major cause of renal dis-
ease and bladder cancer in Africa and the Middle East [41], and yet only 5,500 deaths were
ascribed to all of the world’s 290 million schistosomiasis cases. It is likely that many of the
schistosomiasis-related deaths are being classified in categories such as chronic kidney disease
or bladder cancer, now linked to 956,200 deaths and 173,900 deaths, respectively [4]. Also,
despite the official classification of Opisthorchis viverrini and Clonorchis sinensis as Group 1
carcinogens causing highly fatal cholangiocarcinoma [42], there were no estimated cases of
deaths attributed to foodborne trematodiases. Previous estimates resulted in 7,000–8,000
deaths annually due to cholangiocarcinoma caused by these 2 foodborne liver fluke species,
and even these numbers were considered too low [38, 43, 44]. However, it is likely again that
these deaths were classified as cancer deaths and not as deaths due to foodborne trematodiases.
Similarly, there are 183,400 deaths ascribed to iron-deficiency anemia [4], of which hookworm
disease is a major cause [45], and yet no deaths are attributed to this NTD in the GBD 2013.
These and other factors may result in underreporting of deaths due to diseases such as schisto-
somiasis and hookworm infection. Estimates of dengue may also be too low. The GBD 2013
estimates for deaths from dengue virus range from 8,365 in 1995 to 10,394 in 2010, but in
2013, they decreased to 9,100. Considering the dramatic increase in dengue incidence and geo-
graphic spread of dengue transmission seen in recent years as well as recent evidence on the
underreporting of dengue deaths in well-funded surveillance systems, the number of deaths
due to dengue virus may be substantially higher than that estimated by the GBD study for the
year 2013 [46–49]. A recent systematic review and meta-analysis suggests that estimates of
mortality attributed to Chagas disease may also be low [50]. Similarly, the GBD 2013 estimates
23,500 rabies deaths, but another recent estimate also based on modeling and extensive litera-
ture review estimated 59,000 annual deaths from rabies [51].
For similar reasons, the GBD 2013 also likely underestimates the DALYs attributed to the
NTDs, especially for schistosomiasis and hookworm disease [1]. The DALYs for scabies may
also be an underestimate, as the indirect effects of streptococcal infection on renal and cardio-
vascular function may not be appreciated. Conversely, the DALY estimates for foodborne tre-
matodiasis nearly doubled between GBD 2010 and GBD 2013, from 1.9 million to 3.6 million
DALYs [1, 2]. This surge was caused in part by a revised disability weight for paragonimiasis.
Efforts are underway to harmonize these changes in the upcoming GBD 2015. The corrected
burden estimates for foodborne trematodiases might be in the 2.0–2.5 million DALYs range,
which would also be in line with recently published WHO estimates [38]. For rabies, the GBD
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005424 August 3, 2017 15 / 21
2013 estimated 1.24 million DALYs, but similar to the death estimates, a recent review has esti-
mated 3.7 million DALYs from rabies [51].
While the GBD 2013 provides timely and relevant NTD burden data, critical caveats need
to be clearly stated and considered in the interpretation and application of these estimates.
Among the most frequently mentioned and also critical gaps is the lack of highest-quality epide-
miological data, which is not only an NTD-specific issue but of particular importance for this dis-
ease cluster. Another critical issue—again, not exclusive to NTDs—is the correct modeling of
pathways from infection to disease and death and a correct attribution of the resulting YLDs,
YLLs, and DALYs. Both aforementioned issues ask first and foremost for more primary data from
NTD-specific research in order to strengthen the evidence base and the case of NTDs. However,
there are also methodological decisions in the global burden of disease estimation which need to
be carefully considered. For the sake of shortness, we would like to highlight just 2 of these meth-
odological points which cover the spectrum from (1) practical issues that the NTD community
can address immediately to improve the next generation of GBD estimates to (2) very fundamen-
tal decisions in the design of the DALYs, which the NTD community cannot directly influence
within the massive GBD collaboration but can at least carefully observe and comment.
First, for many country estimates, the GBD disease modeling approach borrows strength
from relevant data in neighboring/similar countries and from additional covariates from a
massive covariate database. However, this may lead to some estimation errors, which are negli-
gible at the global level but relevant at national scale. For instance, Australia is considered
rabies free [52], but GBD reported 2 rabies deaths in Australia. GBD also reports 5 rabies
deaths in the UK just in 2013. However, there have only been 4 rabies deaths in the UK since
2000 (all in individuals bitten by dogs when abroad). Identifying such inconsistencies and pro-
viding guidance to the GBD data analysis team (e.g., force certain country estimates to be
strictly zero) would further improve the precision of GBD estimates. For example, as a poten-
tial strategy for other diseases, autochthonous human case reports on foodborne trematodiases
have been reviewed and mapped by Fu¨rst et al. Thereby, countries were classified (1) as having
suitable national data that should be directly applied in burden estimation, (2) as having no
suitable national data but case reports and where, consequently, national estimates should be
predicted based on the data from similar countries and relevant covariates as the best option,
and (3) as having no suitable national data, no case reports, and as being also not known for its
endemicity, where the models should therefore not predict any cases [53].
Second, since GBD 2010, the GBD studies switched from incidence- to prevalence-based
DALYs [54]. The exact effect of this fundamental decision on the burden estimation and the
comparison of acute with chronic sequelae in populations experiencing varying dynamics is
unclear. This is true in general and hence also for the NTD burden estimates. However, at least
for some NTDs, the readers can refer to the WHO FERG estimates, which provide incidence-
based DALY estimates, in order to obtain a more complete picture on the respective burden
estimates [37–39].
Finally, terms such as prevalence or cases are not always clearly defined in GBD models for
individual diseases, which can create some confusion when interpreting the meaning of the
results. Future iterations of the GBD study will likely be more transparent, making interpreta-
tion simpler and comparison between estimates from other sources more clear.
Concluding remarks
The GBD 2013 highlights reductions in the global prevalence of some specific NTDs such as
LF, onchocerciasis, trachoma, and ascariasis, likely due to MDA, water, sanitation, and hygiene
(WASH) and other control measures, and HAT reductions, likely due to expanded efforts for
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case detection and treatment elimination strategies, especially for the Gambian form of the dis-
ease [10, 15]. In contrast, we have not seen meaningful declines in diseases such as hookworm
infection, trichuriasis, and schistosomiasis, while for dengue, leishmaniasis, and foodborne tre-
matodiases, we have seen substantial increases [3]. Therefore, we need to consider adopting
public health policies to address these trends and adapt our current approaches to specifically
guide better disease surveillance, improved water quality and sanitation, affordable diagnostic
tests, access to healthcare and medications, and further investments in new preventive and dis-
ease-control technologies. We also need to look at shaping NTD control policies in the coun-
tries where NTDs are highest, which include large middle-income countries such as India,
China, and Brazil, where income inequality and the resulting inequality in access to healthcare,
safe housing, clean water, and sanitation has allowed these diseases to persist despite economic
growth [17]. However, GBD 2013 also highlights the high prevalence of NTDs in some of the
smaller conflict-ridden nations and nations in a postconflict period. For example, Liberia,
Central African Republic, South Sudan, and Afghanistan lead the world in several NTD cate-
gories. Creating new strategies to fight NTDs in such countries, which often have highly frac-
tured health infrastructure and struggle to keep hospitals open, poses a different, perhaps more
difficult policy challenge, but is one that should not be ignored. High NTD prevalence was also
noted in several Oceanic and Southeast Asian countries and should also be addressed.
While there are some concerning trends revealed by the GBD 2013, we should not overlook
or downplay the major achievements so far. During the 23 years from 1990 to 2013, much
progress has been made in reducing the prevalence and burden of several NTDs. In the year
2000, the United Nations Millennium Development Goals (MDGs) spurred action against
human immunodeficiency virus, tuberculosis, and malaria. Those actions have paid off in
ensuing years as we are making continued progress in fighting “the big three.” However, goals
specifically targeting NTDs were notably missing from the MDGs beyond a mention of the
“other diseases.” This omission sparked a response from a small group of dedicated NTD activ-
ists to raise the profile of NTDs in the global health community. Since then, we have seen the
creation of a new Department of NTDs at WHO, a Global Network for NTDs, the creation of
NTD research and support centers, and the establishment of programs to support MDA at the
United States Agency for International Development and the British Department for Interna-
tional Development [22]. In addition, several product development partnerships (PDPs) have
formed to develop new NTD drugs, diagnostics, and vaccines, and moreover, major pharma-
ceutical investment in a dengue vaccine has resulted in the first dengue vaccine currently
approved in 3 countries as of January 2016. An open access scientific journal dedicated solely
to NTDs began publication in 2007. The first WHO report on NTDs in 2010 was followed by a
roadmap action plan in 2012, the launch of the END Fund and the London Declaration the
same year, and a specific resolution for NTDs from the World Health Assembly in 2013. Such
efforts have continued beyond 2013 with agreements such as the Addis Ababa NTD Commit-
ment signed at the end of 2014, establishment of the NTD Modeling Consortium, and the
recent inclusion of NTDs in the new UN Sustainable Development Goals. As a result of these
joint efforts, some countries have successfully eliminated certain endemic NTDs. For example,
Mexico was declared to have eliminated onchocerciasis in 2015 following its elimination in
Colombia and Ecuador in 2013 and 2014, respectively [12].
Overall, the results presented here indicate that, despite significant gains, much work
remains in the fight against NTDs. There are still approximately 2.3 billion cases of NTDs,
which cause a substantial global disease burden. It is critical that we as a global community
continue our efforts to help end the suffering caused by NTDs. Helping nations to achieve
health for the poorest of their citizens will be a step forward in achieving their Sustainable
Development Goals. Finally, most of the NTDs are still underreported, and the quantification
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of their burden is limited by the data that are available. Therefore, screening and notification
efforts for the NTDs should be increased in order to capture the true burden of these diseases.
Understanding the true burden of NTDs is essential to track health progress, assess the impact
of public health interventions, and inform evidence-based policy decisions.
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